Related Experiment Video
Updated: Aug 19, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
[Effects of carvedilol (beta 1, beta 2, alpha 1 bloker) on refractory congestive heart failure]
E A Bocchi1, F Bacal, G Bellotti
1Instituto do Coração do Hospital das Clínicas, FMUSP.
Insights
Carvedilol improved heart function and reduced symptoms in patients with severe heart failure. This beta-blocker offers a potential treatment option for refractory heart failure when tolerated.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Severe heart failure management remains challenging.
- The efficacy of beta-blockers in refractory heart failure is not fully understood.
Purpose of the Study:
- To investigate the effects of carvedilol on symptoms, functional class, and left ventricular function in patients with refractory heart failure.
Main Methods:
- A study involving 21 patients with refractory heart failure (NYHA class III/IV).
- Progressive dosage increase of carvedilol, starting at 6.25 mg.
- Evaluations included clinical assessment, ECG, echocardiogram, and MUGA scan after approximately 196 days.
Main Results:
- Carvedilol was well-tolerated in 76% of patients.
- Significant improvements observed in functional class, with most patients moving to class I or II.
- Key cardiac improvements included decreased heart rate, reduced left ventricular end-diastolic diameter, and increased left ventricular ejection fraction.
Conclusions:
- Carvedilol demonstrates potential benefits in improving cardiac function and remodeling in refractory heart failure.
- It may serve as a viable treatment option for patients who tolerate the medication.
- Further research is needed to confirm long-term effects in this patient population.
Purpose:
The effects of beta-blockers on severe heart failure are not well known. We investigated the effects of carvedilol (beta 1, beta 2, alpha 1-blocker) on symptoms, functional class (FC), and left ventricular function in patients with refractory heart failure.
Methods:
We studied 21 patients, mean age 56 +/- 10 years, 9 in FC IV, e 12 in FC III (intermittently with class IV). The initial dosage was 6.25 mg, and it was increased progressively as tolerated. The mean dose was 42 +/- 11 mg. The patients were submitted to routine clinical evaluation, and electrocardiogram. We determined after 196 +/- 60 days of follow-up the left ventricular end diastolic dimension (by echocardiogram), and left ventricular ejection fraction (using MUGA).
Results:
Carvedilol was well tolerated by 16 (76%) patients. One patient is in FC II during increment of the dosage. Eight patients were in FC I, and 7 in FC II at 196 +/- 60 days of follow-up. Heart rate decreased from 96 +/- 15 to 67 +/- 10 bpm (p < 0.0001), left ventricular end diastolic diameter from 73 +/- 13 to 66 +/- 12 mm (p < 0.009), and the left ventricular ejection fraction increased from 0.21 +/- 0.06 to 0.34 +/- 0.12 (p < 0.0003).
Conclusion:
Carvedilol may have beneficial effects on cardiac function, remodeling process, and FC. If tolerated, it seems to be a potential alternative option in the medical treatment of refractory heart failure. However, investigations are still necessary to clarify the long-term effects of carvedilol on this specific subgroup of patients.
More Related Videos
09:12Surgical Swine Model of Chronic Cardiac Ischemia Treated by Off-Pump Coronary Artery Bypass Graft Surgery
Published on: March 27, 2018
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Related Concept Videos
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Antihypertensive Drugs: Types of β-Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: β-Blockers